Fibrolamellar

Fibrolamellar carcinoma is a rare and aggressive type of liver cancer that primarily affects young adults and children, unlike the more common hepatocellular carcinoma, which typically occurs in older individuals with underlying liver disease. This tumor is characterized by its distinct histological appearance, featuring a combination of fibrous and lamellar (layered) structures within the cancerous tissue. The fibrous component often forms a dense, whorled pattern, while the lamellar regions consist of large, polygonal cells with abundant eosinophilic cytoplasm and prominent nucleoli.

The exact cause of fibrolamellar carcinoma remains unclear, but it is not strongly linked to known risk factors such as viral hepatitis or alcohol abuse, which are associated with other liver cancers. Genetic mutations, particularly in the β-catenin gene, have been identified in some cases, suggesting a potential role in tumor development. Diagnosis typically involves imaging studies such as CT or MRI scans, followed by a biopsy to confirm the histological features under a microscope.

Treatment for fibrolamellar carcinoma often includes surgical resection, as the tumor is sometimes localized and removable. However, due to its aggressive nature, recurrence and metastasis are common, and additional therapies such as chemotherapy or targeted drug treatments may be considered in advanced cases. The prognosis varies widely depending on factors such as tumor size, stage at diagnosis, and overall patient health. Research into better diagnostic markers and therapeutic approaches continues, as fibrolamellar carcinoma remains a challenging condition to manage.

This cancer is distinct from fibrolamellar hepatocellular carcinoma, a subtype of hepatocellular carcinoma that shares some histological similarities but differs in clinical behavior and genetic profiles. Further study is needed to fully understand its biology and improve patient outcomes.